Epidemiology of carcinomatosis

IF 2.4 3区医学 Q3 ONCOLOGY

Cancer Epidemiology Pub Date : 2025-04-24 DOI:10.1016/j.canep.2025.102815

Kyle A. Mani , Jun Lu , Eric J. Lehrer , Ming Wang , Lauren E. Henke , Richard S. Hoehn , Nicholas G. Zaorsky

{"title":"Epidemiology of carcinomatosis","authors":"Kyle A. Mani , Jun Lu , Eric J. Lehrer , Ming Wang , Lauren E. Henke , Richard S. Hoehn , Nicholas G. Zaorsky","doi":"10.1016/j.canep.2025.102815","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Carcinomatosis is an advanced form of metastatic cancer, which has been thought to be an invariantly fatal disease. We characterized prognostic factors for overall survival (OS) in patients with de-novo carcinomatosis.</div></div><div><h3>Methods</h3><div>Patients were identified from the SEER database from 1/1/2016–12/31/2020. Kaplan–Meier method and log-rank test were used to evaluate OS and a Cox proportional hazards model was used to calculate adjusted hazard ratios (aHR) with 95 % confidence intervals (CIs).</div><div>We included patients with carcinomatosis across 30 primary sites. The most common primary tumors were colorectal, pancreas, ovary, and lung & bronchus, and stomach.</div></div><div><h3>Results</h3><div>Among newly diagnosed cancer patients in SEER, a total of 3131 (59.7 % female, 80.1 % White) patients with carcinomatosis were identified, corresponding to an incidence of 9.0 per 1000,000 persons. Of all patients with metastatic disease, only 0.17 % were diagnosed with carcinomatosis. Compared to patients with de novo metastatic disease without carcinomatosis (i.e., those with metastases limited to the brain, bone, liver, or lung), patients with carcinomatosis were associated with over twice the risk of mortality (aHR = 2.3, 95 % CI: 2.2–2.5). The 1-year OS for patients with carcinomatosis was 35.8 % (95 % CI: 34.0 %–37.7 %). The most common primary sites included: colorectal (14.8 %), pancreas (14.8 %), ovary (9.8 %), and lung & bronchus (8.9 %). Patients with appendiceal (1-year OS: 88.2 %, 95 % CI: 81.8 %–95.1 %) and ovarian (1-year OS: 58.7 %, 95 % CI: 53.0 %–65.0 %) carcinomatosis had markedly longer survival compared to patients with carcinomatosis from other primary sites. Patients who were at highest risk of death are more likely to be older; male; Black; have more advanced T and N categories; and/or have synchronous metastases (<em>P</em> < .001).</div></div><div><h3>Conclusions</h3><div>Carcinomatosis is associated with poorer OS compared to other forms of metastases. Patients with ovarian and appendiceal tumors have markedly longer survival.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"97 ","pages":"Article 102815"},"PeriodicalIF":2.4000,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Epidemiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S187778212500075X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Carcinomatosis is an advanced form of metastatic cancer, which has been thought to be an invariantly fatal disease. We characterized prognostic factors for overall survival (OS) in patients with de-novo carcinomatosis.

Methods

Patients were identified from the SEER database from 1/1/2016–12/31/2020. Kaplan–Meier method and log-rank test were used to evaluate OS and a Cox proportional hazards model was used to calculate adjusted hazard ratios (aHR) with 95 % confidence intervals (CIs).

We included patients with carcinomatosis across 30 primary sites. The most common primary tumors were colorectal, pancreas, ovary, and lung & bronchus, and stomach.

Results

Among newly diagnosed cancer patients in SEER, a total of 3131 (59.7 % female, 80.1 % White) patients with carcinomatosis were identified, corresponding to an incidence of 9.0 per 1000,000 persons. Of all patients with metastatic disease, only 0.17 % were diagnosed with carcinomatosis. Compared to patients with de novo metastatic disease without carcinomatosis (i.e., those with metastases limited to the brain, bone, liver, or lung), patients with carcinomatosis were associated with over twice the risk of mortality (aHR = 2.3, 95 % CI: 2.2–2.5). The 1-year OS for patients with carcinomatosis was 35.8 % (95 % CI: 34.0 %–37.7 %). The most common primary sites included: colorectal (14.8 %), pancreas (14.8 %), ovary (9.8 %), and lung & bronchus (8.9 %). Patients with appendiceal (1-year OS: 88.2 %, 95 % CI: 81.8 %–95.1 %) and ovarian (1-year OS: 58.7 %, 95 % CI: 53.0 %–65.0 %) carcinomatosis had markedly longer survival compared to patients with carcinomatosis from other primary sites. Patients who were at highest risk of death are more likely to be older; male; Black; have more advanced T and N categories; and/or have synchronous metastases (P < .001).

Conclusions

Carcinomatosis is associated with poorer OS compared to other forms of metastases. Patients with ovarian and appendiceal tumors have markedly longer survival.

查看原文本刊更多论文

癌肿流行病学

背景：癌病是转移性癌症的一种晚期形式，一直被认为是一种永远致命的疾病。我们对新生癌患者总生存期（OS）的预后因素进行了分析。方法从2016年1月1日至2020年12月31日的SEER数据库中筛选患者。采用Kaplan-Meier法和log-rank检验评价OS，采用Cox比例风险模型计算校正风险比（aHR），置信区间为95% %。我们纳入了30个原发部位的癌变患者。最常见的原发肿瘤为结肠、胰腺、卵巢和肺部；支气管和胃。结果在SEER新诊断的癌症患者中，共发现3131例（59.7% %为女性，80.1% %为白人）为癌变患者，发病率为9.0 / 10万人。在所有转移性疾病患者中，只有0.17 %被诊断为癌变。与没有癌变的新发转移性疾病患者（即转移到脑、骨、肝或肺的患者）相比，癌变患者的死亡风险增加了两倍以上（aHR = 2.3, 95 % CI: 2.2-2.5）。癌变患者1年OS为35.8% %（95 % CI: 34.0 % -37.7 %）。最常见的原发部位包括：结直肠（14.8 %）、胰腺（14.8 %）、卵巢（9.8 %）和肺；支气管(8.9 %)。阑尾（1年OS: 88.2 %,95 % CI: 81.8 % -95.1 %）和卵巢（1年OS: 58.7 %,95 % CI: 53.0 % -65.0 %）癌患者的生存期明显长于其他原发部位的癌患者。死亡风险最高的患者年龄更大；男性;黑色;有更高级的T和N类；和/或有同步转移（P <； .001）。结论与其他形式的转移相比，癌性肿瘤的生存期较差。卵巢和阑尾肿瘤患者的生存期明显延长。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Epidemiology 医学-肿瘤学

CiteScore

4.50

自引率

3.80%

发文量

200

审稿时长

39 days

期刊介绍： Cancer Epidemiology is dedicated to increasing understanding about cancer causes, prevention and control. The scope of the journal embraces all aspects of cancer epidemiology including: • Descriptive epidemiology • Studies of risk factors for disease initiation, development and prognosis • Screening and early detection • Prevention and control • Methodological issues The journal publishes original research articles (full length and short reports), systematic reviews and meta-analyses, editorials, commentaries and letters to the editor commenting on previously published research.